Member Info for darkhorse1002

Only days away till June. the antibody tests for home use within grasp. get on board before the train leaves

The silence on updates is killing us….

Someone posted some two weeks ago that we should all ask the company for the update on the ELISA and RTC, but the reaction from this BB was quite negative.

I now agree with the poster, as much as we understand the RTC updates will be dependent on the developments with the consortium and perhaps outside the control of the company, the directors should give an update on the ELISA as this is fully under their control, and its almost one month since the last update - why are we not getting any updates on the commercialisation?

What do you think?

Someone posted some two weeks ago that we should all ask the company for the update on the ELISA and RTC, but the reaction from this BB was quite negative.

I now agree with the poster, as much as we understand the RTC updates will be dependent on the developments with the consortium and perhaps outside the control of the company, the directors should give an update on the ELISA as this is fully under their control, and its almost one month since the last update - why are we not getting any updates on the commercialisation?

What do you think?

gift - i have addded some

once a company reaches these market cap of £300m like AVCT its easier to double your money with companies like MTPH with a market cap of £6m, with technology worthy as much as AVCT, GDR, ODX etc.

Its painful truth!!

cash is circa £13m (including the £3.8m from the recent share raise) vs £6.5 market cap.

Absolute bargain, compared to most Phama/Bio like Motif or Hemo etc, wtih limited cash and no products but speculation

I’m a late comer to NCYT but fully behind this share.

I hardly comment here but curious to see some debates on other BB on the next Novacty? Could MTPH be the next 10 beggar like Novacyt?

dont understand why this is falling when price of oil is going upwards?

I think we are talking the same language, you seem to suggest valuation of 133p (at tangible book value) of the remaining construction business and you agree that the current share price is way over 30% premium to the target share price. Most construction companies trade at a discount to share price. One construction company on LSE/AIM listed company is Infrastructure India Plc -trading at 80% discount to share price.

My view is that there is too much ramping up, my advice is that any price north of 140p is not worth getting into for now.

Agreed with londoner7's post on 3 December 2019 which i have copied below. This SP is for the 'New' Construction business ONLY and the below post is a very good analysis - the estimated share price should be around 100p (which is the default price this morning) and anything above is at your own risk."Hi Boschybear, I've worked out a valuation and was about to post it here when I saw your post. I too have BVS share currently 1200p valued at 1115p for GFRD holders. But I don't think you include the additional dilution due to outstanding share options. Here's my post:As a shareholder I’ve been involved in many bids over the years but this has been one of the hardest to value. The difficulty is the valuation attached to the construction business remaining in GFRD.I’ve tried to break it down based on closing prices 3/12/19 (BVS 1,200p and GFRD 720p). These are my best endeavors so DYOR.I’ve noticed that there are two adjustments from the original bid presentation which negatively impact GFRD shareholders. The most significant is that the fixed number of BVS consideration shares are diluted by the closure of LLP share options, which increases the number of qualifying GFRD shares. The impact is approx. 2% reducing the allocation of BVS shares to 0.56362 per GFRD share. A recent BVS placing increases the capital repayment to £66m, which added to the final dividend equates to a deduction of 85.5p from the current BVS share, i.e. not due to GFRD consideration shares. Fortunately, these activities are netted off by 2nd Jan 2020 so there’s equalization of entitlement from the start of dealings in the new shares 3rd Jan.Crunching the numbers I come to a current valuation of the new construction business at £104m, and a share price of 92p.The prospectus has an adjusted balance sheet (30th June 2019) for the construction business with the debt and cash adjustments showing:Net asset value £237m.Tangible net asset value £151mTherefore, a £104m current valuation represents a 31% discount to tangible net asset value.I’m not attempting to forecast the H1 P&L construction numbers due in Feb 2020. Way beyond my pay grade."londoner7 [ posted on 3 December 2019]

Agreed. This SP is for the 'New' Construction business ONLY and the below post is a very good analysis - the estimated share price should be around 100p (which is the default price this morning) and anything above is at your own risk.

See last note in the accounts: Ordinary Share totalling $419,734 distribution vs current market £500k market cap still a very good return.

KUBC just announced a dividend of US$0.18 vs share price of US$0.21. Ex div date end of next week. Two more assets to sells worth over US$ 12m per last week annual report. It's grossly undervalued. https://www.lse.co.uk/ShareChat.asp?ShareTicker=KUBC&share=Kubera-Cross

A dividend of US$0.18 vs share price of US$0.21. Ex div date end of next week. Two more assets to sells worth over US$ 12m per last week annual report. It's grossly undervalued.